[ad_1]
Drs. Roger Rosenberg, left, and Doris Lambracht-Washington have developed a DNA-based vaccine that reduces the two toxic proteins associated with Alzheimer's disease in mice. The vaccine was tested on three mammals without an undesirable immune response. (Photo: UT Southwestern)
(KUTV) – A DNA vaccine, tested on mice, which could have a major impact on the development of Alzheimer 's disease, could soon be the subject of clinical trials on the subject. ;man.
According to a new study published in Alzheimer's Research and Therapy, the experimental vaccine has reduced the accumulation of two types of toxic proteins considered a cause of Alzheimer's disease, with no adverse effects such as swelling of the brain.
The study, which lasted for ten years, was conducted by the Peter O Donnell Jr. Brain Institute of the University of Texas Southwest.
"If the onset of the disease could be delayed by five years, it would be huge for patients and their families," said Dr. Doris Lambracht-Washington, lead author of the study. "The number of dementia cases could fall by half."
Previous promising vaccines have caused "severe brain swelling" in some patients.
The vaccine delivered by the skin activates an immune response that reduces the accumulation of harmful tau and beta-amyloid.
"This study is the culmination of a decade of research that has repeatedly demonstrated that this vaccine can effectively and safely target animal models that we believe are likely to cause disease." Alzheimer's, "said Dr. Roger Rosenberg, founding director of the Alzheimer's Disease Center at UT. South West. "I think we're about to test this therapy in people."
Until now, it has been safely tested in three mammals and this could soon pave the way for clinical trials.
"The vaccine is on a short list of promising antibody treatments to protect against the two types of proteins that destroy brain cells when they spread deadly plaques in the brains of patients with Alzheimer's disease." declared UT Southwestern.
Alzheimer's disease is gradually worsening the brain of nearly 5.7 million American patients. This number is expected to double by 2050, according to the Centers for Disease Control and Prevention (CDC).
At present, there is no effective treatment for Alzheimer's disease.
The new study indicates that the vaccine might be more effective in patients with high levels of "tau and amyloid stored in the brain", but before the patient has fully developed Alzheimer's disease.
"The longer you wait, the less likely the effect will be," said Dr. Rosenberg. "Once these plates and tangles have formed, it may be too late."
Source link
